Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin

Reviews in Gastroenterological Disorders

Volumn 4, Issue SUPPL. 1, 2004, Pages

  Kontorinis, Nickolas ^a   Agarwal, Kaushik ^a   Dieterich, Douglas T ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

Combination antiviral therapy; Hepatitis C virus; Peginterferon; Ribavirin

Indexed keywords

AMFEBUTAMONE; APPETITE STIMULANT; AZATHIOPRINE; CYCLOSPORIN; DRONABINOL; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; LEVONANTRADOL; MECLOZINE; METOCLOPRAMIDE; MIRTAZAPINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NABILONE; NEFAZODONE; ONDANSETRON; PAROXETINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PHENOTHIAZINE; PLACEBO; PROCHLORPERAZINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; SCATTER FACTOR;

ANEMIA; ANOREXIA; ANTICHOLINERGIC EFFECT; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER TRANSPLANTATION; MOOD DISORDER; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; QUALITY OF LIFE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HOSPITALIZATION; ISOLATION AND PURIFICATION; MALE; MORTALITY; REVIEW; RISK ASSESSMENT; VIRUS LOAD;

ANTIVIRAL AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 3042630841     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995;15:5-14.
2. Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in the East. Semin Liver Dis. 1995;15:15-32.
3. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17-35.
4. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30-S34.
5. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35-S46.
6. McHutchison JG. Hepatitis C advances in antiviral therapy: what is accepted treatment now? J Gastroenterol Hepatol. 2002;17:431-441.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
8. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(suppl 2): S128-S137.
9. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis. 2003;37: 533-541.
10. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
11. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31:997-1004.
12. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G. Factors influencing ribavirin-induced hemolysis. J Hepatol. 2001;34:911-916.
13. Bruchfield A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit. 2002;24:701-708.
14. Lindahl K, Schvarcz R, Bruchfeld A, Stable L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat. 2004; 11:84-87.
15. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail. 1991;13:87-93.
16. Rebetron and Intron A [package inserts]. Kenilworth, NJ: Schering Corp.; 2001.
17. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22:555-565.
18. Hadziyannis SJ, Morgan T. Peginterferon alpha-2a (40KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicenter study examining effect of duration of treatment and RBV dose [abstract]. J Hepatol. 2002;26:3. Abstract 536.
19. Schiffman ML, Lindsay KL. Peginterferon alpha-2a and Ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. In Press.
20. Langston CE, Reine NJ, Kittrell D. The use of erythropoietin. Vet Clin North Am Small Anim Pract. 2003;33:1245-1260.
21. Macdougall IC. Erythropoietin and renal failure. Curr Hematol Rep. 2003;2:459-464.
22. Abdel-Razeq HN. Cancer-related anemia. Saudi Med J. 2004;25:15-20.
23. Glaspy JA. Hematopoietic management in oncology practice. Part 2. Erythropoietic factors. Oncology (Huntingt). 2003;17:1724-1730; discussion 1731-1732, 1735, 1739.
24. Goodnough LT, Despotis GJ. Transfusion medicine: support of patients undergoing cardiac surgery. Am J Cardiovasc Drugs. 2001;1:337-351.
25. Talal AH, Weisz K, Hau T, et al. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol. 2001;96:2802-2804.
26. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003; 98:2491-2499.
27. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
28. Afdhal NH, Pockros PJ. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. In Press.
29. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology. 2002;123:141-151.
30. Wong S, Kaita K, Gauthier T, et al. A comparative trial of recombinant interferon alpha 2A versus alpha 2 beta on myelosuppression in healthy adult volunteers. Hepatogastroenterology. 1996; 43:301-305.
31. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
32. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med. 1999;133:15-22.
33. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
34. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339:1493-1499.
35. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273-1279.
36. Renou C, Harafa A, Bouabdallah R, et al. Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary? Am J Gastroenterol. 2002;97:1260-1263.
37. Chan SE, Rosen HR. Outcome and management of hepatitis C in liver transplant recipients. Clin Infect Dis. 2003;37:807-812.
38. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988; 318:1414-1422.
39. Heil G, HoelzeT D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remisgion induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90:4710-4718.
40. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepalogastroenterology. 1995;42:907-912.
41. Sood A, Russo MW. Use of granulocyte colony stimulating factor (GCSF) for interferon induced neutropenia in patients with chronic hepatitis C infection [abstract 1029]. In: Program and Abstracts of the 52nd Annual Meeting of the AASLD (Dallas, TX). Alexandria, Va.: American Association for the Study of Liver Disease; 2001:429A.
42. Neulasta [package insert]. Thousand Oaks, CA: Amgen; 2002.
43. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 1996;87:3615-3624.
44. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 1997,15:3368-3377.
45. Rustgi VK, Finnegan S, Ershler W. Safety and efficacy of recombinant human IL-11 (oprelvekin) in combination with interferon/ribavirin therapy in hepatitis C patients with thrombocytopenia [abstract 791]. In: Program and Abstracts of the 53rd Annual Meeting of the AASLD (Boston). Alexandria, Va: American Association for the Study of Liver Disease; 2002:361A.
46. Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety 1998;7:188-193.
47. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology. 2000;31:1207-1211.
48. Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant. 1997;11:406-411.
49. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol. 1998;93:785-789.
50. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis. 1999;19(suppl 1):67-75.
51. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36:S237-S244.
52. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis. 1999;19(suppl 1):57-65.
53. Renault PF, Park Y, Mullen KD, et al. Psychiatric complications of long term interferon therapy. Arch Intern Med. 1987;147:1577-1580.
54. Fattovich G. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996; 24:38-47.
55. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986;4:234-253.
56. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54:906-914.
57. Valentine AD, Meyers CA, Kling MA, et al. Mood and cognitive side effects of interferon alfa therapy. Semin Oncol. 1998;25(suppl 1): 39-47.
58. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994;21:241-243.
59. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 1999;57:507-533.
60. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1091-1099.
61. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966.
62. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000;173:359-361.
63. Bhargava HN. Potential therapeutic implications of naturally occurring and synthetic cannabinoids. Gen Pharmacol. 1978;9:195-213.
64. Walsh D, Nelson, KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Cancer Care. 2003;11:137-141.
65. Levitan SA, Uriel A, Kontorinis N, Dieterich DT. Use of dronabinol for treatment of common side effects of chronic hepatitis C therapy. Presented at: Digestive Diseases Week; May 15-20, 2004; New Orleans, La. Abstract 107429.